Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data and AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma and Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
Subscribe
Subscribe

False

The Analytical Scientist / App Notes / 2020 / An Update for Pharmaceutical Stress Testing Enabled by Modern Informatics Technologies

An Update for Pharmaceutical Stress Testing Enabled by Modern Informatics Technologies

03/31/2020

Share

Featured Image

Stress testing or forced degradation is well recognized as a fundamental part of the drug development process, specifically related to purity through control of stability. Control strategies for stability require “stability-indicating” analytical methods, The development and validation of such methods is built on the foundation of well-designed and conducted stress testing studies. The complete regulatory definition of stress testing is found in Q1A(R2).1 An excerpt of this definition is: “stress testing…can help identify the likely degradation products, which can in turn help establish the degradation pathways and the intrinsic stability of the molecule and validate the stability indicating power of the analytical procedures used.” Conditions for stressing include elevated heat and humidity, susceptibility to hydrolysis across a wide pH range, susceptibility to oxidative and photolytic degradation, and in the case of biologics, freeze-thaw cycles and shear (when appropriate).3 The primary goal is to induce pharmaceutically-relevant degradation pathways in a comprehensive manner, at levels that facilitate stability-indicating analytical method development and validation, such that all realistic degradation products (i.e., those formed during manufacturing, handling, and normal storage and distribution conditions) are formed and can be analytically detected. A more comprehensive list of the objectives of stress testing studies can be found elsewhere.4-7 The results of stress testing studies are to “…form an integral part of the information provided to regulatory authorities.”6 More recently, there are additional implications for the control of mutagenic degradation products, as outlined by ICH M7.8

In the last 20 years much has been written on this topic4-7,9-15 including two editions of a book devoted to the topic,6,16 providing helpful guidance on choice of conditions, reasonable endpoints, interpretation of results, and insights into carrying out the studies. This is especially important since the regulatory guidelines are general and do not contain a lot of detail;17 an exception to this is the legislation  and accompanying guidelines19,20 from ANVISA, where many of the requirements21 are unique to Brazil. 

It is helpful to consider that stress testing is predictive in nature, as opposed to definitive. Stress testing is a research tool that is designed to discover potential stability issues with a drug molecule, providing the scientific foundation for developing stability-indicating analytical methods (SAIMs). The use of validated SAIMs for long-term stability studies provide the definitive stability information. A representation of the overall strategy is shown in Figure 1.

Typically, stress testing is not a “one time” event;22 rather it is performed at several stages in the “life cycle” of a novel drug candidate with different goals, strategies, and levels of thoroughness. The regulatory guidance of the FDA does not explicitly require stress testing to be performed or reported during Phase 1–2 stages, although it is encouraged to facilitate the development of stability-indicating methods.23,24 The FDA guidance does require drug substance stress testing for Phase 3 and suggests these studies be conducted on drug products as well. For the New Drug Application (NDA), the guidance requires a summary of DS and DP stress studies including elucidation of degradation pathways, demonstration of the stability-indicating nature of the analytical methods, and identification of significant degradation products.25,26

>> Download the Full Application Note as a PDF

Newsletters

Receive the latest analytical scientist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Explore More in Analytical Science

Dive deeper into the analytical science. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Detection of residual pesticides on fruits and vegetables using Portability™ miniature mass spectrometer
Detection of residual pesticides on fruits and vegetables using Portability™ miniature mass spectrometer

June 9, 2020

Mass spectrometry can be now deployed for onsite pesticide screening in real time...

Routine monitoring of airborne VOCs using TD–GC×GC–TOF MS/FID
Routine monitoring of airborne VOCs using TD–GC×GC–TOF MS/FID

January 15, 2020

The identification and quantitation of volatile organic pollutants in air can be challenging, largely because of the complexity of the samples...

Quantifying trace odorants in water by GC–MS with trap-based preconcentration
Quantifying trace odorants in water by GC–MS with trap-based preconcentration

January 20, 2020

Assessing SPME and high‑capacity sorptive extracti...

Using Self-Aware Agilent InfinityLab LC/MSD iQ to Measure Trace-Level Impurities in a Brand Versus Generic Medication
Using Self-Aware Agilent InfinityLab LC/MSD iQ to Measure Trace-Level Impurities in a Brand Versus Generic Medication

January 22, 2020

This study presents a method for comparison of related impurities in a brand and a generic over-the-counter (OTC) acetaminophen drug...

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.